P275 Platinum compounds (PLcs) added to standard adjuvant or neoadjuvant regimen of doxorubicin plus cyclophosphamide (AC), followed by weekly paclitaxel (wP) in triple negative (TN), HER 2-neu positive (HER 2+) or locally advanced breast cancer (LABC)

Autor: Vassilaki, M., Sioulas, A., Tsantekidou, M., Klitsa, A., Desses, N., Georgakopoulos, C., Kosmidis, C., Tsionou, C., Parassiris, V., Xepapadakis, G.
Zdroj: In The Breast 2011 20 Supplement 1:S66-S66
Databáze: ScienceDirect
Externí odkaz: